Join to access to all OVN content. Join for Free
How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer
MSL Consultant KOL relationships strategic objectives stakeholder mapping Pharma practices

How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer


Share This Article


Summary

My guest today is Aoife O Dwyer, Founder of MSL Consultant, and we discuss how to leverage KOL relationships to achieve strategic objectives.

In this episode:

  • What made Aoife decide to become an MSL Consultant and what she likes best about her role
  • Aoife’s advice to MSLs who want to demonstrate their value to their company
  • Most important things for people to remember in KOL identifications and stakeholder mapping
  • Tips on getting a KOL meeting
  • How can an MSL deliver value in a KOL meeting
  • How can an MSL plan for a KOL meeting
  • How has COVID affected an MSL’s ability to provide value and what advice Aoife can give to MSLs in handling this crisis
  • What skills are now mandatory for MSLs during and after the COVID crisis to provide value to their KOLs and to their organization
  • How Aoife expects Pharma to change practices as a result of Covid-19
  • Advice to MSLs to help aid in their success

Click for Source
MSL Consultant, KOL relationships, strategic objectives, stakeholder mapping, Pharma practices

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Build Scientific Credibility for Continuous Career Development
Partner Avatar MSL Talk: Tom Caravela, Ike Ogbaa

How to Build Scientific Credibility for Continuous Career Development

Podcast
What I DO….How I BUILD Relationships
Partner Avatar MSL Talk: Tom Caravela, Bernadett Mamone

What I DO….How I BUILD Relationships

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN